Over the past several years, the healthcare industry as a whole has experienced an abundance of mergers and acquisitions – major players are buying up their peers in deals ranging from millions to billions. The trend is continuing, and the healthcare playing field continues to be shaped by these mega-transactions. For the medical device industry, […]
Boston Scientific closes $435m Symetis buyout
Boston Scientific (NYSE:BSX) said today that it closed its $435 million buyout of Symetis and its line of minimally invasive replacement heart valves. The buyout, announced in March, halted the 2nd run at an initial public offering by Symetis, which launched the IPO March 20 in a bid to raise up to $66 million (€61.5 million) on the Euronext exchange in […]
Analyst: Boston Scientific could be eyeing a Neovasc buyout
Boston Scientific (NYSE:BSX) is a potential acquirer for mitral valve maker Neovasc (NSDQ:NVCN), according to JMP Securities analyst John Gillings, after agreeing to a $435 million deal for aortic valve maker Symetis that doesn’t include its Middle Peak Medical mitral valve assets. Although the all-cash Symetis deal adds the market-ready Acurate transcatheter aortic valve implant to Boston Scientific’s […]
Boston Scientific puts up $435m for Symetis just ahead of IPO
Boston Scientific (NYSE:BSX) is putting up $435 million in cash for Symetis and its line of minimally invasive replacement heart valves, the companies said today. The buyout halts the 2nd run at an initial public offering by Symetis, which launched the IPO March 20 in a bid to raise up to $66 million (€61.5 million) on the Euronext exchange in Paris. […]
Symetis acquires mitral valve maker Middle Peak Medical
Symetis said yesterday that it acquired Middle Peak Medical, and the transcatheter mitral valve replacement device it’s developing, for an undisclosed amount. Middle Peak, which counts Edwards Lifesciences (NYSE:EW) among its backers, is developing a TMVR device that’s designed to simulate the shape of the posterior leaflet to stop mitral regurgitation. Lausanne, Switzerland-based Symetis said the buyout is […]
Symetis sets range for $96m IPO
(Reuters) — Symetis, a Swiss maker of replacement heart valve devices, said it has set a price range for its initial sale of shares between 35 and 46 Swiss francs ($36.16-$47.53), as it seeks to raise money from investors for business expansion and R&D. At the midpoint the flotation would fetch CHF 93.2 million ($96.2 million). Symetis […]
TAVI: Symetis battles the big dogs
Switzerland-based medical implant maker Symetis is looking to make some major moves in the global transcatheter aortic valve implantation market, and the company’s not afraid to take on some of the medtech industry’s biggest players.
Press Release: Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system
LAUSANNE, SWITZERLAND – Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of ACURATE neo, its 15F compatible transfemoral TAVI system. Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer.
TAVI: Symetis chases Medtronic and Edwards with E.U. win for Acurate neo heart valve
Stealthy Swiss device maker Symetis announced today that it’s launching commercial sales of its Acurate neo transfemoral transcatheter aortic valve implantation system, having just won CE Mark approval from European regulators.
Device makers team up for next-gen TAVI system
Medical device makers Symetis Inc. and Endoluminal Sciences are reaching across oceans to co-develop a new generation of transcatheter aortic valve implantation systems featuring "active anti-paravalvular leak technology."
The duo entered into a license agreement to incorporate Endoluminal Sciences’ anti-leak system into Symetis’ Acurate TA and Acurate TF product lines, according to a press release.
Symetis touts positive findings for its Acurate TA TAVI system
Swiss medical device maker Symetis released 30-day registry findings for its 2nd-generation transcatheter aortic valve implantation systems, touting high procedural success rates and minimal valve leakage.
Results from the SAVI postmarket registry highlighted findings from the 1st 250 patients implanted with Symetis’ Acurate TA TAVI system, which won European regulatory approval in September 2011.
